AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) had its price target lowered by Citigroup Inc. to $24.00 in a research report report published on Friday, The Fly reports. The brokerage currently has a hold rating on the specialty pharmaceutical company’s stock.
A number of other research firms have also recently issued reports on AMAG. Jefferies Group LLC set a $40.00 price target on AMAG Pharmaceuticals and gave the company a buy rating in a report on Saturday, March 18th. Cantor Fitzgerald reaffirmed a hold rating and issued a $23.00 price target on shares of AMAG Pharmaceuticals in a report on Tuesday, May 2nd. Barclays PLC reaffirmed a hold rating and issued a $25.00 price target on shares of AMAG Pharmaceuticals in a report on Friday, May 5th. TheStreet cut AMAG Pharmaceuticals from a c rating to a d+ rating in a report on Friday, May 5th. Finally, ValuEngine cut AMAG Pharmaceuticals from a hold rating to a sell rating in a report on Thursday, May 11th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of Hold and an average target price of $28.09.
Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) opened at 19.67 on Friday. AMAG Pharmaceuticals has a 12-month low of $16.00 and a 12-month high of $36.83. The firm’s market cap is $689.51 million. The company has a 50 day moving average of $18.02 and a 200-day moving average of $23.21.
AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings data on Tuesday, May 2nd. The specialty pharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.09 by $1.15. The company had revenue of $139.47 million for the quarter, compared to the consensus estimate of $150.32 million. AMAG Pharmaceuticals had a negative net margin of 5.61% and a positive return on equity of 1.69%. The firm’s revenue was up 27.6% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.22) earnings per share. Equities research analysts forecast that AMAG Pharmaceuticals will post $5.12 EPS for the current fiscal year.
In other AMAG Pharmaceuticals news, SVP Julie Krop sold 1,891 shares of the business’s stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $24.45, for a total transaction of $46,234.95. Following the completion of the sale, the senior vice president now directly owns 36,777 shares of the company’s stock, valued at approximately $899,197.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 3.80% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. Cornerstone Financial Partners LLC raised its position in AMAG Pharmaceuticals by 306.3% in the first quarter. Cornerstone Financial Partners LLC now owns 49,492 shares of the specialty pharmaceutical company’s stock valued at $1,116,000 after buying an additional 37,312 shares during the last quarter. Bank of Montreal Can raised its position in AMAG Pharmaceuticals by 4,071.4% in the first quarter. Bank of Montreal Can now owns 66,492 shares of the specialty pharmaceutical company’s stock valued at $1,500,000 after buying an additional 64,898 shares during the last quarter. Creative Planning raised its position in AMAG Pharmaceuticals by 768.4% in the first quarter. Creative Planning now owns 13,895 shares of the specialty pharmaceutical company’s stock valued at $313,000 after buying an additional 12,295 shares during the last quarter. Teachers Advisors LLC raised its position in AMAG Pharmaceuticals by 9.5% in the fourth quarter. Teachers Advisors LLC now owns 59,891 shares of the specialty pharmaceutical company’s stock valued at $2,084,000 after buying an additional 5,216 shares during the last quarter. Finally, Norges Bank bought a new position in AMAG Pharmaceuticals during the fourth quarter valued at about $19,914,000.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.